Effect of MMF on interstitial lung disease associated with collagen vascular diseases

Effect of MMF on interstitial lung disease associated with collagen vascular diseases - MMF for CVD-ILD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220173

Enrollment

Registered

2014-03-26

Start date

2011-11-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

interstitial lung disease associated with collagen vascular diseases

Interventions

Intervention type:DRUG Name of intervention:mycophenolate mofetil,mycophenolate mofetil Dose form / Japanese Medical Device Nomenclature:CAPSULE,CAPSULE Route of administration / Site of application:O

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: interstitial lung disease associated with collagen vascular diseases resistant to conventional therapy

Exclusion criteria

Exclusion criteria: physician's decision

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
efficacy	—

Countries

Japan

Contacts

Public ContactToshinori Takada

Niigata University Medical and Dental Hospital

ttakada@med.niigata-u.ac.jp+81-25-227-0378

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026